Showing results (131-140 of 403) with videos related to

Sort By:
Pageof 41
Scientific Data|December 6, 2017
Corrigendum: Transcriptomic profiling of 39 commonly-used neuroblastoma cell linesJo Lynne Harenza, Maura A Diamond, Rebecca N Adams, et al.
Pediatric Blood & Cancer|April 11, 2007
Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing programPeter J Houghton, Christopher L Morton, E Anders Kolb, et al.
Pediatric Blood & Cancer|February 23, 2008
Initial testing (stage 1) of sunitinib by the pediatric preclinical testing programJohn M Maris, Joshua Courtright, Peter J Houghton, et al.
Pediatric Blood & Cancer|March 27, 2015
Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane(®)) by the Pediatric Preclinical Testing Program (PPTP)Peter J Houghton, Raushan T Kurmasheva, E Anders Kolb, et al.
Plos One|March 1, 2007
Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arraysRani E George, Edward F Attiyeh, Shuli Li, et al.
Pediatric Blood & Cancer|May 27, 2015
Treatment of neuroblastoma in congenital central hypoventilation syndrome with a PHOX2B polyalanine repeat expansion mutation: New twist on a neurocristopathy syndromeAmy E Armstrong, Debra E Weese-Mayer, Amir Mian, et al.
Pediatric Blood & Cancer|June 26, 2009
Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing programHernan Carol, Richard Lock, Peter J Houghton, et al.
Frontiers in Oncology|March 27, 2020
CAMKV Is a Candidate Immunotherapeutic Target in MYCN Amplified NeuroblastomaRobyn T Sussman, Jo Lynne Rokita, Kevin Huang, et al.
Pediatric Blood & Cancer|February 9, 2008
Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing programMalcolm A Smith, Christopher L Morton, Doris A Phelps, et al.
Plos One|August 12, 2016
Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for NeuroblastomaShigeki Yagyu, Tomoko Iehara, Shiro Tanaka, et al.
Pageof 41